Folx Health is a new telehealth startup, built for the transgender community., and it plans to target the underserved market for queer sexual health and wellness. Available in all 50 States, the company has already raised $25 million of venture funding in a Series A round, getting off to a good start.
The telehealth startup will operate on a subscription basis, with patients paying a fee starting at $59 USD per month. Folx will be offering online consultation with doctors, as well as home-delivered hormone replacement therapy prescriptions and a variety of resources (these can be found in 'The Library'). This is just the initial step, however. The telehealth startup is planning to expand into "treatment for erectile dysfunction, sexually transmitted infection, pre-exposure prophylaxis, and the ability to take lab samples at home."
Transgender-Focused Telehealth Startups
Folx Gives New Options to Marginalized Communities
Trend Themes
1. Transgender Telehealth Services - Opportunity for new telehealth startups to provide specialized healthcare services to marginalized communities.
2. Online Hormone Replacement Therapy - Opportunity for startups to provide accessible and convenient hormone replacement therapy services through telehealth platforms.
3. Expanded Telehealth Offerings - Opportunity for telehealth startups to offer a wider range of medical services, including sexual health and wellness consultations and treatments, lab sample collection and testing, and erectile dysfunction treatment.
Industry Implications
1. Healthcare - Opportunity for the healthcare industry to address the needs of marginalized communities and provide specialized telehealth services.
2. Telehealth - Opportunity for the telehealth industry to expand their services to include sexual health and wellness, hormone replacement therapy, and home lab testing.
3. Pharmaceuticals - Opportunity for pharmaceutical companies to invest in the development of specialized hormone replacement therapy medication and treatments for the transgender community.